NCT07191717
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07191717
Title Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial
Acronym MIRI
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Jonsson Comprehensive Cancer Center
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.